<?xml version="1.0" encoding="UTF-8"?>
  	<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9"><url>
      <loc>https://www.onclive.com/view/elticertinib-receives-fda-fast-track-designation-in-egfr-exon-20-mutated-nsclc</loc>
      <lastmod>2026-11-18T22:11:09.658Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T22:11:09.658Z</news:publication_date>
        <news:title><![CDATA[Elticertinib Receives FDA Fast Track Designation in EGFR Exon 20–Mutated NSCLC]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/fda-grants-breakthrough-therapy-designation-to-daretabart-for-newly-diagnosed-high-risk-neuroblastoma</loc>
      <lastmod>2026-11-18T21:55:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T21:55:00Z</news:publication_date>
        <news:title><![CDATA[FDA Grants Breakthrough Therapy Designation to Daretabart for Newly Diagnosed High-Risk Neuroblastoma]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/exploratory-insights-into-early-tolerability-and-treatment-experience-with-vyloy-zolbetuximab-clzb-in-spotlight-and-glow</loc>
      <lastmod>2026-11-18T19:24:02.712Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T19:24:02.712Z</news:publication_date>
        <news:title><![CDATA[Exploratory Insights into Early Tolerability and Treatment Experience with VYLOY® (zolbetuximab-clzb) in SPOTLIGHT and GLOW]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/can-ai-fix-clinical-trial-access-in-oncology-arturo-loaiza-bonilla-md-built-the-answer-with-the-data-to-back-it</loc>
      <lastmod>2026-11-18T18:51:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T18:51:00Z</news:publication_date>
        <news:title><![CDATA[Can AI Fix Clinical Trial Access in Oncology? Arturo Loaiza-Bonilla, MD, Built the Answer With the Data to Back It ]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/longitudinal-community-training-helps-prepare-oncology-fellows-for-their-future-careers</loc>
      <lastmod>2026-11-18T18:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T18:00:00Z</news:publication_date>
        <news:title><![CDATA[Longitudinal Community Training Helps Prepare Oncology Fellows for Their Future Careers]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/natalee-dellphi-305-interpath-001-and-litespark-012-headline-key-oncology-data-from-esmo-2026</loc>
      <lastmod>2026-11-18T15:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T15:00:00Z</news:publication_date>
        <news:title><![CDATA[NATALEE, DeLLphi-305, INTerpath-001, and LITESPARK-012 Headline Key Oncology Data From ESMO 2026]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/galinpepimut-s-improves-os-in-aml-in-second-or-later-remission</loc>
      <lastmod>2026-11-18T14:21:56.157Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T14:21:56.157Z</news:publication_date>
        <news:title><![CDATA[Galinpepimut-S Improves OS in AML in Second or Later Remission]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/community-care-pathways-in-squamous-nsclc</loc>
      <lastmod>2026-11-18T13:05:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T13:05:00Z</news:publication_date>
        <news:title><![CDATA[Community Care Pathways in Squamous NSCLC]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/interpreting-subgroup-analyses</loc>
      <lastmod>2026-11-18T13:05:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T13:05:00Z</news:publication_date>
        <news:title><![CDATA[Interpreting Subgroup Analyses]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/detecting-met-driven-resistance-and-the-saffron-survival-data</loc>
      <lastmod>2026-11-18T13:05:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T13:05:00Z</news:publication_date>
        <news:title><![CDATA[Detecting MET-Driven Resistance and the SAFFRON Survival Data]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/emerging-cell-surface-targets-and-neuroendocrine-biomarkers-in-prostate-cancer</loc>
      <lastmod>2026-11-18T13:05:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T13:05:00Z</news:publication_date>
        <news:title><![CDATA[Emerging Cell Surface Targets and Neuroendocrine Biomarkers in Prostate Cancer]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/initial-diagnostic-work-up-for-suspected-nets</loc>
      <lastmod>2026-11-18T13:05:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T13:05:00Z</news:publication_date>
        <news:title><![CDATA[Initial Diagnostic Work-Up for Suspected NETs]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/updated-kandlelit-001-data-show-durable-responses-with-frontline-calderasib-plus-pembrolizumab</loc>
      <lastmod>2026-11-18T13:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T13:00:00Z</news:publication_date>
        <news:title><![CDATA[Updated KANDLELIT-001 Data Show Durable Responses With Frontline Calderasib Plus Pembrolizumab in KRAS G12C–Mutated NSCLC]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/sequencing-all-comer-regimens-after-first-line-egfr-therapy</loc>
      <lastmod>2026-11-18T13:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T13:00:00Z</news:publication_date>
        <news:title><![CDATA[Sequencing All-Comer Regimens After First-Line EGFR Therapy]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/evaluating-non-brca-hrr-alterations-for-parp-inhibitor-therapy</loc>
      <lastmod>2026-11-18T13:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T13:00:00Z</news:publication_date>
        <news:title><![CDATA[Evaluating Non-BRCA HRR Alterations for PARP Inhibitor Therapy]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/patient-centered-treatment-selection-and-shared-decision-making-in-relapsed-refractory-multiple-myeloma</loc>
      <lastmod>2026-11-18T13:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T13:00:00Z</news:publication_date>
        <news:title><![CDATA[Patient-Centered Treatment Selection and Shared Decision-Making in Relapsed/Refractory Multiple Myeloma]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/somatostatin-receptors-and-circulating-biomarkers-in-nets</loc>
      <lastmod>2026-11-18T13:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T13:00:00Z</news:publication_date>
        <news:title><![CDATA[Somatostatin Receptors and Circulating Biomarkers in NETs]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/applying-trial-eligibility-to-clinical-practice</loc>
      <lastmod>2026-11-18T13:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T13:00:00Z</news:publication_date>
        <news:title><![CDATA[Applying Trial Eligibility to Clinical Practice]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/monitoring-and-managing-ctla-4-toxicities-in-squamous-nsclc</loc>
      <lastmod>2026-11-18T13:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T13:00:00Z</news:publication_date>
        <news:title><![CDATA[Monitoring and Managing CTLA-4 Toxicities in Squamous NSCLC]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/esmo-2026-data-highlight-adc-activity-in-brain-metastases-and-tnbc</loc>
      <lastmod>2026-11-18T01:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T01:00:00Z</news:publication_date>
        <news:title><![CDATA[ESMO 2026 Data Highlight ADC Activity in Brain Metastases and TNBC]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/sintilimab-receives-positive-chmp-opinion-for-first-line-nonsquamous-nsclc</loc>
      <lastmod>2026-11-18T00:55:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T00:55:00Z</news:publication_date>
        <news:title><![CDATA[Sintilimab Receives Positive CHMP Opinion for First-Line Nonsquamous NSCLC]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/fda-removes-limitations-of-use-for-liso-cel-in-primary-central-nervous-system-lymphoma</loc>
      <lastmod>2026-11-17T21:22:18.713Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T21:22:18.713Z</news:publication_date>
        <news:title><![CDATA[FDA Removes Limitations of Use for Liso-Cel in Primary Central Nervous System Lymphoma]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/quality-improvement-and-egfr-mutatnt-lung-cancer-survivorship-research-help-shape-fellowship-training</loc>
      <lastmod>2026-11-17T21:16:57.173Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T21:16:57.173Z</news:publication_date>
        <news:title><![CDATA[Quality Improvement and EGFR-Mutant Lung Cancer Survivorship Research Help Shape Fellowship Training]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/long-term-sano-data-reinforce-active-surveillance-as-an-option-in-esophageal-cancer</loc>
      <lastmod>2026-11-17T21:08:23.383Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T21:08:23.383Z</news:publication_date>
        <news:title><![CDATA[Long-Term SANO Data Reinforce Active Surveillance as an Option in Esophageal Cancer ]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/perioperative-targeted-therapy-fills-the-immunotherapy-gap-in-oncogene-driven-early-stage-nsclc</loc>
      <lastmod>2026-11-17T20:47:25.166Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T20:47:25.166Z</news:publication_date>
        <news:title><![CDATA[Perioperative Targeted Therapy Fills the Immunotherapy Gap in Oncogene-Driven Early-Stage NSCLC]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/payloads-therapeutic-windows-biomarkers-shape-next-wave-of-adcs-in-nsclc</loc>
      <lastmod>2026-11-17T20:15:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T20:15:00Z</news:publication_date>
        <news:title><![CDATA[Beyond the Target: Payloads, Therapeutic Windows, and Biomarkers Shape the Next Wave of ADCs in NSCLC]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/fda-accepts-snda-for-selinexor-plus-ruxolitinib-in-myelofibrosis</loc>
      <lastmod>2026-11-17T18:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T18:00:00Z</news:publication_date>
        <news:title><![CDATA[FDA Accepts sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/fda-approves-neladalkib-for-locally-advanced-or-metastatic-alk-nsclc</loc>
      <lastmod>2026-11-17T17:40:32.625Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T17:40:32.625Z</news:publication_date>
        <news:title><![CDATA[FDA Approves Neladalkib for Locally Advanced or Metastatic ALK+ NSCLC]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/tcr-based-strategies-and-tolerable-combinations-begin-to-narrow-the-outcome-gap-in-uveal-melanoma</loc>
      <lastmod>2026-11-17T14:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T14:00:00Z</news:publication_date>
        <news:title><![CDATA[TCR-Based Strategies and Tolerable Combinations Begin to Narrow the Outcome Gap in Uveal Melanoma]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/her2-mutation-and-overexpression-in-lung-cancer</loc>
      <lastmod>2026-11-17T13:05:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T13:05:00Z</news:publication_date>
        <news:title><![CDATA[HER2 Mutation and Overexpression in Lung Cancer]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/rosella-trial-design-survival-results-and-subgroup-findings</loc>
      <lastmod>2026-11-17T13:05:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T13:05:00Z</news:publication_date>
        <news:title><![CDATA[ROSELLA Trial Design, Survival Results, and Subgroup Findings]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/pd-l1-and-immunotherapy-selection-in-gastrointestinal-cancers</loc>
      <lastmod>2026-11-17T13:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T13:00:00Z</news:publication_date>
        <news:title><![CDATA[PD-L1 and Immunotherapy Selection in Gastrointestinal Cancers]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/using-relacorilant-plus-nab-paclitaxel-earlier-in-platinum-resistance</loc>
      <lastmod>2026-11-17T13:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T13:00:00Z</news:publication_date>
        <news:title><![CDATA[Using Relacorilant Plus Nab-Paclitaxel Earlier in Platinum Resistance]]></news:title>
      </news:news>
	</url></urlset>